Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
NCT05565326

Response Assessment During MR-guided Radiation Therapy for Glioblastoma

Led by University of Zurich · Updated on 2025-03-03

20

Participants Needed

1

Research Sites

173 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The study seeks to assess the response of glioblastoma multiforme to treatment using weekly low field (0.35 T) MR-images of the brain at a MRIdian® linac system during standard radiotherapy at the same system. A total of 20 patients in a single arm will be recruited for this investigation. The imaging data will be used to evaluate the change in tumor volume over the course of the treatment and to perform radiomics in order to investigate the possibility of response prediction using these images. In order to assure sufficient image quality, prior to the main investigation, a group of up to 20 volunteers has MR scans taken with identical sequences to the main study phase.

CONDITIONS

Official Title

Response Assessment During MR-guided Radiation Therapy for Glioblastoma

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent according to Swiss law and ICH/GCP before any study procedures
  • Histologically confirmed diagnosis of glioblastoma multiforme
  • Indication for fractionated radiation therapy for glioblastoma multiforme
  • Age 18 years or older
  • Any gender
  • Karnofsky performance status of 60 or higher
  • Willing and able to comply with scheduled visits, treatment, and study procedures
Not Eligible

You will not qualify if you...

  • Previous cranial radiation therapy
  • Contraindications to MRI, such as non-compatible implantable devices or metallic foreign bodies
  • Inability to complete MRI due to claustrophobia
  • Pregnancy or breastfeeding
  • Intention to become pregnant during the study
  • Lack of safe contraception for women of childbearing potential during the study
  • Uncontrolled illness including active infection, diabetes, symptomatic heart failure, unstable angina, or arrhythmia
  • Known or suspected non-compliance, drug or alcohol abuse
  • Inability to follow study procedures due to language, psychological, or cognitive issues
  • Participation in another investigational drug study within 30 days before or during this study
  • Investigator or close relations employed or dependent on the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Hospital Zurich

Zurich, Canton of Zurich, Switzerland, 8091

Actively Recruiting

Loading map...

Research Team

M

Michael Mayinger, MD

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here